Literature DB >> 32586178

MiR-199a-3p inhibits the proliferation, migration, and invasion of endothelial cells and retinal pericytes of diabetic retinopathy rats through regulating FGF7 via EGFR/PI3K/AKT pathway.

Lin Zhou1, Suozhi Zhang2, Lijuan Zhang3, Fangfang Li1, Hao Sun1, Jun Feng1.   

Abstract

PURPOSE: MiR-199a-3p is low expressed in diabetic retinopathy (DR). In the current study, we investigated the effects of miR-199a-3p on DR and the potential mechanisms.
METHODS: A DR rat model was established, and endothelial cells (ECs) and retinal pericytes (RPs) were extracted from the DR model rats to detect miR-199a-3p expression. Bioinformatics analysis predicted that fibroblast growth factor 7 (FGF7) was a target gene for miR-199a-3p, which was confirmed by dual-luciferase assay. Cell proliferation, migration, and invasion were detected by cell counting kit-8 (CCK-8), colony formation assay, wound-healing, and Transwell assay. Quantitative real-time polymerase chain reaction (q-PCR) and Western blot were performed to detect the expressions of mRNAs and proteins.
RESULTS: MiR-199a-3p was low expressed and FGF7 was high-expressed in ECs and RPs. Overexpressed miR-199a-3p suppressed the proliferation, migration, and invasion, and FGF7 expression of ECs and RPs. However, overexpression of FGF7 effectively eliminated the suppressive effects of miR-199a-3p overexpression malignant behaviors of the cells. Meanwhile, up-regulation of FGF7 noticeably reversed the phosphorylation of phosphoinositide 3-kinase (PI3K) and protein kinase B (AKT) and the expression of epidermal growth factor receptor (EGFR) reduced by miR-199a-3p.
CONCLUSION: Our findings revealed that in the DR rat model, miR-199a-3p inhibited cell proliferation, migration, and invasion of EC and RP through targeting FGF7 and inhibiting the activation of the EGFR/PI3K/AKT pathway. This study may provide a new direction for the search for the treatment of DR.

Entities:  

Keywords:  Diabetic retinopathy; EGFR/PI3K/AKT; FGF7; miR-199a-3p

Mesh:

Substances:

Year:  2020        PMID: 32586178     DOI: 10.1080/10799893.2020.1783556

Source DB:  PubMed          Journal:  J Recept Signal Transduct Res        ISSN: 1079-9893            Impact factor:   2.092


  6 in total

1.  The potential effects and mechanisms of hispidulin in the treatment of diabetic retinopathy based on network pharmacology.

Authors:  Yao Chen; Jiaojiao Sun; Zhiyun Zhang; Xiaotong Liu; Qiaozhi Wang; Yang Yu
Journal:  BMC Complement Med Ther       Date:  2022-05-19

2.  Network Pharmacology-Based Approach to Comparatively Predict the Active Ingredients and Molecular Targets of Compound Xueshuantong Capsule and Hexuemingmu Tablet in the Treatment of Proliferative Diabetic Retinopathy.

Authors:  Hongyan Yao; Danli Xin; Zongyi Zhan; Zijing Li
Journal:  Evid Based Complement Alternat Med       Date:  2021-03-05       Impact factor: 2.629

3.  Tribbles Homolog 3 Mediates the Development and Progression of Diabetic Retinopathy.

Authors:  Priyamvada M Pitale; Irina V Saltykova; Yvonne Adu-Agyeiwaah; Sergio Li Calzi; Takashi Satoh; Shizuo Akira; Oleg Gorbatyuk; Michael E Boulton; Machelle T Pardue; W Timothy Garvey; Mohammad Athar; Maria B Grant; Marina S Gorbatyuk
Journal:  Diabetes       Date:  2021-05-11       Impact factor: 9.337

4.  Investigating the Mechanisms of Pollen Typhae in the Treatment of Diabetic Retinopathy Based on Network Pharmacology and Molecular Docking.

Authors:  Rongrong Zhou; Yuqing Zhang; Liyun Duan; Yuehong Zhang; Yingying Duan; Xiaomin Kang; Fengmei Lian
Journal:  Evid Based Complement Alternat Med       Date:  2022-01-03       Impact factor: 2.629

5.  miR-199a-3p/5p regulate tumorgenesis via targeting Rheb in non-small cell lung cancer.

Authors:  Xiaomin Liu; Xianyi Wang; Binshu Chai; Zong Wu; Zhitao Gu; Heng Zou; Hui Zhang; Yanli Li; Qiangling Sun; Wentao Fang; Zhongliang Ma
Journal:  Int J Biol Sci       Date:  2022-06-27       Impact factor: 10.750

6.  Construction and Validation of an Autophagy-Related Prognostic Signature and a Nomogram for Bladder Cancer.

Authors:  Xin Yan; Hua-Hui Wu; Zhao Chen; Guo-Wei Du; Xiao-Jie Bai; Kurerban Tuoheti; Tong-Zu Liu
Journal:  Front Oncol       Date:  2021-06-18       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.